PUBLISHER: The Business Research Company | PRODUCT CODE: 1760592
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760592
Leukocytosis is a condition characterized by an elevated white blood cell (WBC) count in the bloodstream, often indicating an underlying infection, inflammation, or immune response. The primary purpose of treating this condition is to strengthen the body's defense mechanisms by increasing the number of WBCs to combat infections or heal injuries.
The main types of diseases associated with leukocytosis include infections, inflammation, leukemia, and stress response. Infections trigger leukocytosis as the immune system responds to invading pathogens by boosting the production of white blood cells (particularly neutrophils) to combat bacterial threats. Diagnosis of leukocytosis typically involves blood tests, bone marrow biopsies, and imaging techniques. The condition is managed and treated through various distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies. Key end users of leukocytosis-related diagnostics and treatments include hospitals, diagnostic laboratories, and research institutions.
The leukocytosis market research report is one of a series of new reports from The Business Research Company that provides leukocytosis market statistics, including leukocytosis industry global market size, regional shares, competitors with an leukocytosis market share, detailed leukocytosis market segments, market trends and opportunities, and any further data you may need to thrive in the leukocytosis industry. The leukocytosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The leukocytosis market size has grown strongly in recent years. It will grow from $4.89 billion in 2024 to $5.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth during the historic period can be attributed to several factors, including the increasing incidence of infections and inflammatory diseases, rising awareness and diagnosis of blood disorders, a higher prevalence of leukemia and other cancers, a growing aging population susceptible to immune dysfunction, and an increase in hospital admissions for chronic illnesses.
The leukocytosis market size is expected to see strong growth in the next few years. It will grow to $6.39 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The projected growth during the forecast period can be attributed to several factors, including the increasing prevalence of chronic illnesses such as cancer and autoimmune diseases, the rising demand for early and precise diagnostic solutions, a growing elderly population prone to immune system dysfunction, heightened awareness and routine health check-ups leading to early detection, and the overall increase in global healthcare spending. Key trends expected during the forecast period include the integration of artificial intelligence into diagnostic tools, the development of portable point-of-care leukocyte count devices, the adoption of telemedicine platforms for remote patient monitoring, advancements in automated leukocyte counting technologies, and the use of digital health records to enable personalized treatment strategies.
The increasing occurrence of blood-related disorders is anticipated to drive the growth of the leukocytosis market in the coming years. These disorders involve medical conditions that impact the components of blood, including red and white blood cells, platelets, and plasma. The prevalence of such diseases is rising, particularly due to aging populations, as older individuals are more prone to conditions such as anemia, leukemia, and clotting disorders because of weakened immune systems and accumulated health complications. These disorders frequently result in elevated white blood cell counts-a key indicator of leukocytosis-underscoring the need for improved early detection, better monitoring solutions, and more effective treatment methods. For example, in 2024, the American Cancer Society, a US-based cancer organization, reported 62,770 new cases of leukemia, marking a notable increase from 59,610 cases in 2023. Consequently, the increasing prevalence of blood-related diseases is fueling the growth of the leukocytosis market.
Leading companies in the leukocytosis market are increasingly incorporating artificial intelligence into diagnostic platforms to improve early disease detection, enhance diagnostic precision, and support personalized treatment strategies. AI-powered diagnostic tools utilize technologies such as machine learning, deep learning, and natural language processing to interpret medical data and aid in or automate disease diagnosis. For instance, in December 2024, Koninklijke Philips NV, a healthcare firm based in the Netherlands, introduced the CT 5300 system. This system integrates proprietary AI technologies to optimize computed tomography (CT) imaging processes. It includes the CT smart workflow, which features AI-powered tools such as Precise Position, Precise Cardiac, and Precise Brain to streamline scan setup, increase diagnostic accuracy, and minimize radiation exposure.
In February 2024, AbbVie Inc., a US-based biopharmaceutical company, completed the acquisition of ImmunoGen Inc. for an undisclosed sum. This strategic move bolsters AbbVie's oncology pipeline by incorporating ImmunoGen's specialized capabilities in antibody-drug conjugates (ADCs), enhancing the company's efforts to develop targeted treatments for blood-related cancers and conditions such as leukocytosis. ImmunoGen Inc. is a biotechnology company based in the US that focuses on ADCs for treating blood cancers, including leukemia, which frequently leads to leukocytosis.
Major players in the leukocytosis market are McKesson Corporation, Pfizer Inc., Johnson & Johnson, Siemens Healthineers AG, Roche Diagnostics AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis International AG, Danaher Corporation, Merck KGaA, Becton, Dickinson and Company (BD), Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, Agilent Technologies Inc., Grifols SA, Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Beckman Coulter Diagnostics Inc, Bio-Rad Laboratories, Bio-Techne Corporation, NeoGenomics Laboratories, Inc., DiaSorin S.p.A., DiaSorin S.p.A.
North America was the largest region in the leukocytosis market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in leukocytosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the leukocytosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The leukocytosis market includes revenues earned by entities through complete blood count (CBC) testing, white blood cell differential analysis, monitoring and management of underlying conditions, development and administration of targeted therapeutics, and support for clinical research and drug trials focused on hematologic abnormalities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Leukocytosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on leukocytosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for leukocytosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leukocytosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.